IBA (Ion Beam Applications), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency ...

After recent discussions with the DRDC, the research study on Bucillamine is now set to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation for effect size. Positive ...

Louvain-la-Neuve, Belgique, 12 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") ...

(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) ...